Hopwood Financial Services Inc. purchased a new stake in shares of Novartis AG (NYSE:NVS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 2,425 shares of the company's stock, valued at approximately $236,000.
Several other institutional investors and hedge funds have also bought and sold shares of NVS. Atria Investments Inc raised its position in Novartis by 0.4% in the 3rd quarter. Atria Investments Inc now owns 46,040 shares of the company's stock valued at $5,296,000 after buying an additional 191 shares during the last quarter. Mesirow Financial Investment Management Inc. raised its stake in shares of Novartis by 2.7% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 4,573 shares of the company's stock worth $526,000 after purchasing an additional 119 shares during the period. Crossmark Global Holdings Inc. grew its position in shares of Novartis by 28.2% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 35,617 shares of the company's stock valued at $4,096,000 after acquiring an additional 7,824 shares during the period. Catalytic Wealth RIA LLC increased its position in Novartis by 21.3% in the third quarter. Catalytic Wealth RIA LLC now owns 4,689 shares of the company's stock worth $539,000 after buying an additional 822 shares during the last quarter. Finally, Addison Advisors LLC raised its stake in Novartis by 4.5% in the 3rd quarter. Addison Advisors LLC now owns 2,783 shares of the company's stock valued at $320,000 after acquiring an additional 121 shares during the period. 13.12% of the stock is owned by institutional investors.
Novartis Price Performance
Shares of NYSE:NVS opened at $111.48 on Wednesday. Novartis AG has a twelve month low of $92.35 and a twelve month high of $120.92. The company has a current ratio of 1.04, a quick ratio of 0.84 and a debt-to-equity ratio of 0.48. The company has a market cap of $227.87 billion, a PE ratio of 18.96, a price-to-earnings-growth ratio of 1.70 and a beta of 0.53. The company's 50 day moving average is $104.66 and its 200 day moving average is $107.82.
Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings data on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. On average, sell-side analysts forecast that Novartis AG will post 8.45 EPS for the current year.
Wall Street Analyst Weigh In
Several equities analysts recently commented on the company. Barclays restated an "underweight" rating on shares of Novartis in a research report on Monday, February 3rd. Erste Group Bank reiterated a "hold" rating on shares of Novartis in a report on Tuesday, November 19th. StockNews.com upgraded shares of Novartis from a "buy" rating to a "strong-buy" rating in a report on Saturday, February 8th. HSBC cut Novartis from a "hold" rating to a "reduce" rating in a research note on Wednesday, December 4th. Finally, Morgan Stanley started coverage on shares of Novartis in a research note on Wednesday, February 12th. They issued an "underweight" rating on the stock. Three analysts have rated the stock with a sell rating, six have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $123.38.
Check Out Our Latest Research Report on Novartis
Novartis Company Profile
(
Free Report)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
See Also
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
